Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.52 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.52 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.52 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31365231 | 1.00 | CYP2B6 (0.52) | CYP2B6TENT4ATENT4BCNR2KDM4E | |
| SCHEMBL22898996 | 0.92 | CYP2B6 (0.46) | CYP2B6TENT4ATENT4B | |
| SCHEMBL22898918 | 0.91 | CYP2B6 (0.45) | CYP2B6TENT4ATENT4BCNR2 | |
| SCHEMBL21358161 | 0.86 | CYP2B6 (0.58) | CYP2B6TENT4ATENT4BCNR2KDM4E | |
| SCHEMBL27200083 | 0.85 | CYP2B6 (0.41) | CYP2B6TENT4ATENT4B | |
| SCHEMBL31365208 | 0.85 | CYP2B6 (0.41) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21360017 | 0.84 | CYP2B6 (0.46) | CYP2B6TENT4ATENT4B | |
| SCHEMBL21360034 | 0.84 | CYP2B6 (0.46) | CYP2B6TENT4ATENT4B | |
| SCHEMBL31365200 | 0.82 | CYP2B6 (0.42) | CYP2B6TENT4ATENT4BCNR2KDM4E | |
| SCHEMBL27200107 | 0.82 | CYP2B6 (0.42) | CYP2B6TENT4ATENT4BCNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964986-B1 | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives | REJUVERON TELOMERE THERAPEUTICS AG (CH) | 2024-04-23 | — | — | US | disclosed |
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-07-18 | — | — | US | disclosed |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702427-B2 | Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same | HAVCR2, HPD, CYP24A1 | CYP2B6 19/4885TENT4A 921/4885TENT4B 1050/4885 |
| US-20210017186-A1 | SUBSTITUTED 2-PYRIDONE TRICYCLIC COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, HPD, CYP24A1 | CYP2B6 19/4885TENT4A 921/4885TENT4B 1050/4885 |
| US-11964986-B1 | 9-oxo-9,10-dihydro-6H-pyrano[3,2-b:4,5-b′]dipyridine-8-carboxylic acid derivatives | DPP9, DPYD, QDPR | CYP2B6 26/4885TENT4A 2925/4885TENT4B 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.